YARW — YARROW BIOSCIENCE Share News
0.000.00%
Last trade - 00:00- $181.86m
- $158.94m
- $0.57m
U.S. STOCKS ON THE MOVE-Piedmont Lithium, Walmart, Kilroy Realty
U.S. STOCKS ON THE MOVE-Walmart, JD.Com, Crinetics
U.S. STOCKS ON THE MOVE-Neogen Corp, Freight Technologies, Philip Morris
VYNE Therapeutics jumps as skin disorder treatment shows promise
Brief: VYNE Therapeutics Announces Positive Data From Phase 1a Trial For VYN201
Brief: VYNE Therapeutics Reports Year-End 2022 Financial Results
Brief: Vyne Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Rule
Brief: Vyne Therapeutics Announces Positive Results From Phase 1A Single And Multiple Ascending Dose Trial
Brief: Vyne Therapeutics Announces Reverse Stock Split
U.S. STOCKS ON THE MOVE-Oatly, Inari Medical, Netflix
U.S. STOCKS ON THE MOVE-Qualigen Therapeutics, Albertsons, ICON
U.S. STOCKS ON THE MOVE-Danaher, Bumble, Vyne Therapeutics
Vyne Therapeutics rises as early-stage trial dosing of skin drug starts
Brief: Vyne Therapeutics Announces First Vitiligo Patient Dosed In Phase 1A/B Clinical Trial Of Novel Bet Inhibitor Vyn201
Brief: VYNE Therapeutics Announces First Patent Granted For Novel BET Inhibitor Platform
Brief: Vyne Therapeutics Announces First Subjects Dosed In Phase 1a/b Clinical Trial Evaluating Pan-BET Inhibitor, VYN201, For The Treatment Of Vitiligo
Brief: VYNE Therapeutics Reports Third Quarter 2022 Financial Results, Provides Business Update
Vyne Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Vyne Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview